Role of SMAD and non-SMAD signals in the development of Th17 and regulatory T cells

L Lu, J Wang, F Zhang, Y Chai, D Brand… - The Journal of …, 2010 - journals.aai.org
L Lu, J Wang, F Zhang, Y Chai, D Brand, X Wang, DA Horwitz, W Shi, SG Zheng
The Journal of immunology, 2010journals.aai.org
Whereas TGF-β is essential for the development of peripherally induced Foxp3+ regulatory
T cells (iTreg cells) and Th17 cells, the intracellular signaling mechanism by which TGF-β
regulates development of both cell subsets is less understood. In this study, we report that
neither Smad2 nor Smad3 gene deficiency abrogates TGF-β–dependent iTreg induction by
a deacetylase inhibitor trichostatin A in vivo, although the loss of the Smad2 or Smad3 gene
partially reduces iTreg induction in vitro. Similarly, SMAD2 and SMAD3 have a redundant …
Abstract
Whereas TGF-β is essential for the development of peripherally induced Foxp3+ regulatory T cells (iTreg cells) and Th17 cells, the intracellular signaling mechanism by which TGF-β regulates development of both cell subsets is less understood. In this study, we report that neither Smad2 nor Smad3 gene deficiency abrogates TGF-β–dependent iTreg induction by a deacetylase inhibitor trichostatin A in vivo, although the loss of the Smad2 or Smad3 gene partially reduces iTreg induction in vitro. Similarly, SMAD2 and SMAD3 have a redundant role in development of Th17 in vitro and in experimental autoimmune encephalomyelitis. In addition, ERK and/or JNK pathways were shown to be involved in regulating iTreg cells, whereas the p38 pathway predominately modulated Th17 and experimental autoimmune encephalomyelitis induction. Therefore, selective targeting of these intracellular TGF-β signaling pathways during iTreg and Th17 cell development might lead to the development of therapies in treating autoimmune and other chronic inflammatory diseases.
journals.aai.org